Earnings summaries and quarterly performance for ASP Isotopes.
Executive leadership at ASP Isotopes.
Board of directors at ASP Isotopes.
Research analysts who have asked questions during ASP Isotopes earnings calls.
Recent press releases and 8-K filings for ASPI.
ASP Isotopes Extends Renergen Acquisition Fulfillment and Loan Repayment Dates
ASPI
M&A
Debt Issuance
New Projects/Investments
- ASP Isotopes Inc. (ASPI) and Renergen Limited have extended the fulfillment date for their proposed scheme of arrangement to January 30, 2026, from the previously extended date of November 28, 2025.
- This extension is primarily to allow additional time for regulatory approval from the Financial Surveillance Department of the South African Reserve Bank (FinSurv) and certain third-party consents required for the acquisition.
- Under the scheme, Renergen shareholders will receive 0.09196 new ASPI shares for each Renergen share held.
- Concurrently, the final repayment date for the $30,000,000 term loan facility provided by ASPI to Renergen has also been extended to January 30, 2026.
7 days ago
ASPI Provides Q3 2025 Business Update, Highlights Strong Cash Position and Strategic Progress
ASPI
Earnings
M&A
New Projects/Investments
- ASPI reported a cash balance of $113.9 million as of September 30, 2025, supported by $56.3 million in net proceeds from stock issuance during Q3 2025 and an additional $199.7 million received in October 2025.
- The company is awaiting final regulatory approval for the Renergen acquisition, which is expected to generate free cash flow during 2026.
- ASPI secured its largest Silicon-28 contract to date for delivery in 2026 and completed its first Ytterbium-176 production plant, with commercial delivery anticipated in 1H 2026.
- Quantum Leap Energy (QLE) confidentially submitted its S-1 registration statement for an IPO and spin-off to the SEC on November 12, 2025, and acquired a controlling stake in Skyline Builders Group Holding Limited, which will be rebranded as Super Critical Materials Inc..
Nov 21, 2025, 1:30 PM
ASPI Reports Q3 2025 Results, Advances Acquisitions and Spin-off Plans
ASPI
Earnings
M&A
New Projects/Investments
- ASP Isotopes reported a net loss from operations of $34.9 million for year-to-date 2025, compared to $18.7 million for the same period in 2024, with year-to-date operating expenses increasing 84% to $36.2 million.
- The company's cash on hand as of September 30, 2025, was $113.9 million, supplemented by an additional $200 million received from common stock issuance subsequent to the quarter-end.
- Operationally, ASP Isotopes is producing silicon-28 and ytterbium-176, with commercial deliveries for both anticipated in the first half of 2026. The company also expanded its radiopharmaceutical footprint by acquiring East Coast Nuclear in Florida.
- Strategically, the Renergen acquisition is nearing completion, pending one final regulatory approval. Its subsidiary, Quantum Leap Energy (QLE), has filed S-1 documentation for a planned spin-off in Q4 2025 and raised $64.3 million via convertible notes. QLE is also pursuing opportunities in LEU Plus and HALEU production.
Nov 21, 2025, 1:30 PM
ASP Isotopes Reports Q3 2025 Financials and Operational Progress
ASPI
Earnings
M&A
New Projects/Investments
- ASP Isotopes reported Q3 2025 radiopharmaceutical revenues of $1.3 million, an 18% increase year-over-year, and year-to-date 2025 radiopharmaceutical revenues of $3.6 million, a 24% increase year-over-year. The company concluded Q3 2025 with $113.9 million in cash.
- The company is nearing completion of the Renergen acquisition, with final regulatory approval pending, and acquired a controlling stake in Skyline Builders. Additionally, a proposed acquisition of Supercritical aims to establish Quantum Leap Energy as a comprehensive nuclear fuel company.
- Key operational advancements include the enrichment of silicon-28 with commercial samples validated and the production of ytterbium-176, with commercial deliveries anticipated in the first half of 2026. The company plans to begin construction of new isotope enrichment plants in Iceland, the US, and the UK during 2026.
- Management reiterated the previously indicated $50-$70 million revenue opportunity for 2026-2027 from Ytterbium-176 and Silicon-28, while noting that updated detailed guidance will be provided once corporate events are concluded.
Nov 21, 2025, 1:30 PM
ASP Isotopes Provides Q3 2025 Operational and Strategic Update
ASPI
M&A
New Projects/Investments
Guidance Update
- ASP Isotopes (ASPI) reported significant operational progress in Q3 2025, with its multi-isotope plant enriching silicon-28 and the first quantum enrichment plant producing ytterbium-176, with commercial deliveries expected in H1 2026. The carbon plant is expected to ship commercial carbon-12 in December and carbon-14 in H1 2026.
- The company is advancing several strategic acquisitions, including the near-complete Renergen acquisition and the acquisition of a controlling stake in Skyline Builders, which subsequently raised $41.7 million and proposed the acquisition of Supercritical to secure nuclear fuel feedstocks.
- Quantum Leap Energy (QLE), ASPI's nuclear energy subsidiary, raised $64.3 million via convertible note, bringing its pro forma cash on hand to $81.6 million, and filed S-1 documentation for a planned IPO in Q4 2025. QLE is also exploring LEU Plus production (5-10% enrichment) for customer inquiries.
- Property and equipment grew from approximately $23 million at December 31, 2024, to $33 million at September 30, 2025, primarily due to plant construction in South Africa. The company reiterated its prior guidance of a $50-$70 million revenue opportunity in 2026 and 2027 for Ytterbium-176 and Silicon-28, but is not yet updating detailed forecasts.
Nov 21, 2025, 1:30 PM
ASP Isotopes Subsidiary Announces Convertible Note Offering
ASPI
Debt Issuance
New Projects/Investments
- ASP Isotopes Inc.'s wholly-owned subsidiary, Quantum Leap Energy LLC (QLE), entered into a Convertible Note Purchase Agreement on November 7, 2025, to issue approximately $64.3 million in QLE 2025 Notes.
- The net proceeds from this offering are intended for the development of QLE's laser enrichment production facilities and general corporate purposes.
- Upon the initial closing, QLE's outstanding 2024 Convertible Notes, with an expected principal and accrued interest of $29,531,405.11 as of November 14, 2025, will automatically convert into additional QLE 2025 Notes with an expected principal amount of $147,657,020.
- The QLE 2025 Notes will accrue interest at 8.0% per annum, are due five years from the initial closing, and are general unsecured obligations of QLE, with ASPI not acting as a guarantor.
Nov 14, 2025, 9:47 PM
ASPI Subsidiary Quantum Leap Energy Confidentially Submits Draft IPO Registration Statement
ASPI
New Projects/Investments
- ASP Isotopes Inc. announced on November 12, 2025, that its wholly-owned subsidiary, Quantum Leap Energy LLC (QLE), has confidentially submitted a draft registration statement on Form S-1 to the SEC.
- This submission is for a proposed initial public offering (IPO) of QLE's Class A common stock.
- The number of shares to be offered and the price range for the proposed offering have not yet been determined.
- The proposed IPO is subject to the completion of the SEC review process and other market conditions.
Nov 12, 2025, 9:31 PM
ASPI Subsidiary Quantum Leap Energy Announces Convertible Note Private Placement
ASPI
Debt Issuance
New Projects/Investments
- Quantum Leap Energy LLC (QLE), a wholly-owned subsidiary of ASP Isotopes Inc. (ASPI), announced a private placement of convertible notes.
- The initial closing of the offering is for US$64.3 million in aggregate principal amount of QLE's convertible notes.
- The offering was led by ASPI and American Ventures LLC, with capital contributions from Eric Trump and Donald Trump Jr., and the initial closing is expected on or about November 10, 2025.
- QLE intends to use the net proceeds from the offering to build and develop laser enrichment production facilities and for general corporate purposes.
Nov 7, 2025, 2:31 PM
ASP Isotopes' UK Subsidiary Begins Regulatory Engagement for HALEU Production
ASPI
New Projects/Investments
Management Change
- ASP Isotopes Inc.'s UK subsidiary, Quantum Leap Energy Ltd. (QLE Ltd.), has commenced early engagement with UK nuclear regulators for new nuclear projects.
- This process aims to establish regulatory pathways for QLE Ltd. to become the first commercial producer of High-Assay Low Enriched Uranium (HALEU) in the UK.
- Rich Deakin has been appointed as Senior Vice President and Managing Director UK Strategic Projects for QLE Ltd., bringing over 35 years of nuclear industry experience.
- The company anticipates a potential pathway to full licensing within this decade for its uranium enrichment operations.
Nov 5, 2025, 1:24 PM
ASP Isotopes Announces Proposed Public Offering of Common Stock
ASPI
- On October 14, 2025, ASP Isotopes Inc. announced it is commencing an underwritten public offering of shares of its common stock.
- The offering is subject to market conditions, with no assurance regarding its completion, actual size, or terms.
- Cantor and Lucid Capital Markets are acting as joint book-running managers for the offering.
- The offering is being made pursuant to a shelf registration statement filed with the SEC on October 14, 2025, which became immediately effective upon filing.
Oct 16, 2025, 10:16 AM
Quarterly earnings call transcripts for ASP Isotopes.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more
Let Fintool AI Agent track ASP Isotopes's earnings for you
Get instant analysis when filings drop